MedTrace Logo

Lithium Cannabis Withdrawal Study

NCT00114439 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2007-09-27

No results posted yet for this study

Summary

This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.

Conditions

  • Cannabis Dependence
  • Substance Withdrawal Syndrome

Interventions

DRUG

Lithium carbonate

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Sydney South West Area Health Service

    lead OTHER_GOV

Principal Investigators

  • Adam R Winstock, MBBS BSc MSc MRCP(UK) MRCP · Corella Drug Treatment Service

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Completion
2006-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00114439 on ClinicalTrials.gov